Amgen's US$4 billion monoclonal antibody is in crisis? This new domestic Class 2 drug is here

Table 1: The basic situation of the new drug accepted(source: listed company announcement)announcement mentioned that the new drug to the United States Amin company has been listed abroad monoclonal antibody drug monoantigen as the imitation target, the development of amino acid sequence and tinnitus monoantigen completely consistent with biological products class 2 new drugs, indications for high risk of fracture risk of menopausal female osteoporosisFigure 1: Dino single anti-global sales(source: Minet multi-national listed company sales database)According to Minet data, in 2018, The global sales of Sino-Monoantion more than $4 billion, of which sales for the treatment of osteoporosis reached $2.291 billion, a growth rate of 16.4%;May 2019, Amgen's Tinnomono-resistance (known as dishu-mono-resistance) was approved by the State Drug Administration for treatment of non-surgical lyctoma syketosoma synomeoma synodoma synoda and adolescent patients with mature bone development that may lead to severe dysfunction, but the current pronomono resistance to postmenopausal women with postmenopausal osteoporosis increased risk of fractures has not been listed in Chinathe current clinical treatment program of osteoporosis in China mainly to bisphosphonates, estrogen, estrogen receptor regulators and calcite-reducing traditional small molecules, hormones and peptide drugs, tinnoprosy as the first single-clone antibody based on THE successful development of RANKL, innovative in clinical applicationsThe tnobutiadi based on RANKL target is the only successful new drug listed in the field of osteoporosis in recent years, its clinical application is wide, because of its few adverse reactions, higher safety, easy to use, better patient compliance and so on, Tinnomonotades in foreign (UK and UK) the main guidelines have occupied an important therapeutic position, Kun Pharmaceutical Group said that the development of the new drug coincides with the strategic layout currently under way by the Group in the field of biopharmaceuticals, while Dino monoantigen as a potential heavyweight product for domestic osteoporosis treatment, and is highly consistent with the current major coverage areas of Baker Norton, a subsidiary of Kun Pharmaceutical Group, and is expected to strengthen Baker Norton's dominant position in the field of orthopaedics in the futuresources: Internet database, announcement of listed companies